Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BXRX Baudax Bio (BXRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Baudax Bio Stock (NASDAQ:BXRX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Baudax Bio alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.01▼$3.47Volume310,800 shsAverage Volume281,029 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Read More… Remove Ads Receive BXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BXRX Stock News HeadlinesBaudax Bio Announces Corporate UpdateOctober 18, 2023 | finance.yahoo.comBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug TagOctober 2, 2023 | msn.comElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.April 1, 2025 | InvestorPlace (Ad)Why Is Baudax Bio (BXRX) Stock Up 75% Today?September 28, 2023 | investorplace.comBaudax Bio Shares Double After Orphan Drug Designation for TI-168September 28, 2023 | marketwatch.comBaudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With InhibitorsSeptember 28, 2023 | markets.businessinsider.comHere's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock NowSeptember 18, 2023 | finance.yahoo.comBaudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceSeptember 7, 2023 | finance.yahoo.comSee More Headlines BXRX Stock Analysis - Frequently Asked Questions How were Baudax Bio's earnings last quarter? Baudax Bio, Inc. (NASDAQ:BXRX) issued its quarterly earnings results on Wednesday, August, 16th. The company reported ($1.49) earnings per share for the quarter, topping the consensus estimate of ($2.04) by $0.55. When did Baudax Bio's stock split? Baudax Bio's stock reverse split before market open on Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Baudax Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Vanguard Dividend Appreciation ETF (VIG), Vanguard Total Stock Market ETF (VTI), iShares Russell 1000 Growth ETF (IWF), Schlumberger (SLB), ARK Innovation ETF (ARKK), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/16/2023Today4/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BXRX CIK1780097 Webwww.baudaxbio.com Phone484-395-2440Fax484-395-2471Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,790,000.00 Net MarginsN/A Pretax Margin-18,950.64% Return on EquityN/A Return on Assets-175.11% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.27 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($14.93) per share Price / Book0.00Miscellaneous Outstanding Shares52,460,000Free Float52,408,000Market Cap$1.14 million OptionableNot Optionable Beta1.57 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BXRX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baudax Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.